Trials / Sponsors / Angiochem Inc
Angiochem Inc
Industry · 8 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Unknown | ANG1005 in Leptomeningeal Disease From Breast Cancer Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases | Phase 3 | 2023-12-01 |
| Completed | ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Breast Cancer, Brain Metastases | Phase 2 | 2014-04-01 |
| Completed | ANG1005 in Patients With Recurrent High-Grade Glioma Glioma, Glioblastoma, Brain Tumor, Recurrent | Phase 2 | 2013-10-01 |
| Terminated | GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) Non-small Cell Lung Cancer (NSCLC) With Brain Metastases | Phase 2 | 2011-11-01 |
| Completed | GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Breast Cancer, Brain Metastases | Phase 2 | 2011-10-01 |
| Completed | A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Advanced Solid Tumors With and Without Brain Metastases | Phase 1 | 2007-10-01 |
| Completed | A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma Recurrent or Progressive Malignant Glioma | Phase 1 | 2007-10-01 |
| No Longer Available | Expanded Access to ANG1005 for Individual Patients Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases | — | — |